Summary
The aim of conducting this study was to assess the clinical relevance of matrix metalloproteinase (MMP) inhibition by doxycycline, an effective MMP inhibitor, in a rat model of extensive myocardial infarction (MI) and left ventricular (LV) dysfunction. Rats (n = 22) were subjected to extensive anterior MI. Doxycycline (25 mg SC, daily) or saline (control) injections were started for nine days thereafter. The effect of doxycycline on MMP activity in the infarcted and remote myocardium was measured by zymography, in another subgroup (n = 8), nine days after MI. Echocardiography and magnetic resonance imaging (MRI) studies were performed at one and thirty days after MI to assess LV remodeling and function. After 4 weeks, hearts were fixed, and subjected to morphometric and histological analysis. Compared with control, doxycycline treatment attenuated MMP-9 and -2 activity in both infarcted and remote myocardium. Serial echocardiography studies showed that doxycycline failed to attenuate scar thinning, LV dilatation and dysfunction. MRI study showed that doxycycline impaired LV compensatory hypertrophy. Furthermore, compared with control, doxycycline reduced vessel density (/mm2 ± SEM) in the infarcted myocardium (84 ± 16 vs. 46 ± 9/mm2, respectively; p < 0.05).
Our work suggest that effective MMPs’ inhibition in the infarcted and remote myocardium by doxycycline does not prevent LV remodeling and dysfunction but impairs angiogenesis and compensatory LV hypertrophy. Our findings caution against aggressive, non-selective inhibition of MMPs in the early healing phase after MI.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: When is enough enough? Circulation 2003;108:1395–1403.
Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999;100:999–1008.
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000;101:2981–2988.
Jessup M, Brozena S. Heart Failure. N Engl J Med 2003;348:2007–2018.
Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003;108:1487–1492.
Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001;89:201–210.
Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail 2002;8:S332–S338.
Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target. Cardiovasc Res 2000;46:225–238.
Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 2000;135:316–323.
Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002;90:520–530.
Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003;285:H1229–H1235.
Ramani R, McTiernan CF. The matrix strikes back: Evidence for autoregulatory mechanisms in metalloproteinase regulation. J Mol Cell Cardiol 2003;35:603–606.
Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996;23:336–246.
Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543–1549.
Camp TM, Tyagi SC, Aru GM, Hayden MR, Mehta JL. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 2004;23:729–736.
Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005;45:657–687.
Etzion S, Battler A, Barbash IM, et al. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol 2001;33:1321–1330.
Lu L, Zhang JQ, Ramires FJ, Sun Y. Molecular and cellular events at the site of myocardial infarction: From the perspective of rebuilding myocardial tissue. Biochem Biophys Res Commun 2004;320:907–913.
Reich R, Blumenthal M, Liscovitch M. Role of phospholipase D in laminin-induced production of gelatinase A (MMP-2) in metastatic cells. Clin Exp Metastasis 1995;13:134–140.
Barbash IM, Leor J, Feinberg MS, et al. Interventional magnetic resonance imaging for guiding gene and cell transfer in the heart. Heart 2004;90:87–91.
Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063–3070.
Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55–62.
Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: Acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998;28:1082–1093.
Lamparter S, Slight SH, Weber KT. Doxycycline and tissue repair in rats. J Lab Clin Med 2002;139:295–302.
Lindsey ML, Gannon J, Aikawa M, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002;105:753–758.
Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. Angiogenesis: Vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 2003;10:136–141.
Puyraimond A, Weitzman JB, Babiole E, Menashi S. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells. J Cell Sci 1999;112(Pt 9):1283–1290.
Haas TL, Milkiewicz M, Davis SJ, et al. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000;279:H1540–H1547.
Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625–637.
Kollet O, Shivtiel S, Chen YQ, et al. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest 2003;112:160–169.
Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: Potential role in capillary branching. Circ Res 2004;94:262–268.
Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 2000;156:1865–1873.
Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135–1142.
Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004;109:2572–2580.
Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003;108:1753–1759.
Cleland JG, Coletta AP, Freemantle N, Velavan P, Tin L, Clark AL. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005;7:931–936.
Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001;103:2181–2187.
Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303–2309.
Beekman B, Verzijl N, de Roos JA, Koopman JL, TeKoppele JM. Doxyclycline inhibits collagen synthesis by bovine chondrocytes cultured in alginate. Biochem Biophys Res Commun 1997;237:107–110.
Chapman RE, Scott AA, Deschamps AM, et al. Matrix metalloproteinase abundance in human myocardial fibroblasts: Effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol 2003;35:539–548.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tessone, A., Feinberg, M.S., Barbash, I.M. et al. Effect of Matrix Metalloproteinase Inhibition by Doxycycline on Myocardial Healing and Remodeling after Myocardial Infarction. Cardiovasc Drugs Ther 19, 383–390 (2005). https://doi.org/10.1007/s10557-005-5201-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-005-5201-6